Affiliation:
1. Department of Anesthesiology and Critical Care, Arak University of Medical Sciences, Arak, Iran
2. Clinical Research Development, Valiasr Hospital, Arak University of Medical Sciences, Arak, Iran
Abstract
Objective:
To assess the effects of L-carnitine on the outcomes of patients with moderate to severe coronavirus disease 2019 (COVID-19) in intensive care unit (ICU).
Methods:
This double-blind clinical trial was carried out in 2022-2023. 64 Patients with COVID-19 were selected from Amiralmomenin and Khansari hospitals in Arak, Iran. They were randomly assigned to the control and the L-carnitine treatment group via block randomization. Venous blood gases, disease severity, and levels of D-dimer, lactate dehydrogenase, ferritin, and C-reactive protein were daily assessed during the seven days of the intervention, and the length of ICU stay, the need for endotracheal intubation, and mortality rate were documented.
Results:
There were significant differences in length of ICU stay, the need for endotracheal intubation, and levels of D-dimer, lactate dehydrogenase, ferritin, APACHE II score, and C-reactive protein between the two groups (P<0.05). However, the groups did not significantly differ in mortality rate and venous blood gas indexes (P>0.05).
Conclusions:
L-carnitine can improve outcomes of patients with COVID-19. Therefore, it can be used as an adjuvant therapy for these patients.
Trial registration:
Iranian Registry of Clinical Trials identifier IRCT20141209020258N165.
Reference34 articles.
1. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - An update on the status;Guo;Mil Med Res,2020
2. Maternal death due to severe and critical COVID-19 in Qom, Iran: A case series;Yousefzadeh;J Acute Dis,2022
3. Respiratory infections in the aging lung: Implications for diagnosis, therapy, and prevention;Häder;Aging Dis,2023
4. COVID-19 and management of severe acute respiratory infection (SARI): A questionnaire-based study among indian healthcare professionals;Patankar;Curr Health Sci J,2020
5. COVID-19 (Coronavirus disease 2019): A new coronavirus disease;Sadeghi;Infect Drug Resist,2020